“This article introduces the research progress of 177Lu labeled peptide radiopharmaceuticals in the field of tumor therapy. Experts have explored strategies such as polymerization, dual targeted design, and blood half-life extension modification, providing a key technical path for improving targeted peptide tumor retention.”
Journal of Radiation Research and Radiation ProcessingVol. 44, Issue 1, Pages: 10102(2026)
作者机构:
1.中国原子能科学研究院 北京 102413
2.重庆市万州粮油质量监督检验站 重庆 404001
作者简介:
XU Qianlong (male) was born in March 2000, graduated from Dalian University of Technology in July 2022 with a bachelor's degree. Now, he is a graduate student at the China Institute of Atomic Energy, focusing on radiopharmaceuticals
LI Fenglin, professor, E-mail: lifenglin@ciae.ac.cn
XU Qianlong, LI Fenglin, FENG Hejuan, et al. The development of 177Lu labelled peptides[J]. Journal of Radiation Research and Radiation Processing, 2026, 44(1): 010102.